Cargando…

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration

BACKGROUND: Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the commonly used BRAF inhibitor vemurafenib, affect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maximova, Natalia, Maestro, Alessandra, Zanon, Davide, Marcuzzi, Annalisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057420/ https://www.ncbi.nlm.nih.gov/pubmed/32066648 http://dx.doi.org/10.1136/jitc-2019-000388

Ejemplares similares

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
por: Pinard, Camille, et al.
Publicado: (2017)

Nevirapine-induced rash with eosinophilia and systemic symptoms (DRESS)
por: Gill, Shaman, et al.
Publicado: (2013)

Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome
por: Young, Peter A., et al.
Publicado: (2021)

Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Due to Vancomycin
por: Kulkarni, Mugdha P, et al.
Publicado: (2022)

Histopathological Characterization of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) and Comparison with Maculopapular Drug Rash (MPDR)
por: Jindal, Rashmi, et al.
Publicado: (2022)

Standard treatment–refractory cytomegalovirus encephalitis unmasked by immune reconstitution inflammatory syndrome and successfully treated with virus‐specific hyperimmune globulin
por: Maximova, Natalia, et al.
Publicado: (2020)

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: a narrative review
por: Manieri, Elisa, et al.
Publicado: (2023)

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Celecoxib and Anti-tuberculosis Drugs
por: Lee, Joo Ho, et al.
Publicado: (2008)

Bilateral acute angle closure as presenting feature of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)
por: Sanoria, Abhilasha, et al.
Publicado: (2019)

Polycyclic rash with persistent eosinophilia
por: Merz, Lauren E., et al.
Publicado: (2021)

Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study
por: Maximova, Natalia, et al.
Publicado: (2023)

Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient with rheumatoid arthritis
por: Massolino, Rose I, et al.
Publicado: (2018)

Post-Irradiation Hyperamylasemia Is a Prognostic Marker for Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Pediatric Population: A Retrospective Single-Centre Cohort Analysis
por: Baldo, Francesco, et al.
Publicado: (2021)

Papulopustular Rash Due to Tocilizumab
por: Kohro-Kawata, Junko, et al.
Publicado: (2019)

Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report
por: Fachin, Alice, et al.
Publicado: (2023)

Eosinophilia in Amoxicillin-Induced Rash in Infectious Mononucleosis
por: Abreu, Ana, et al.
Publicado: (2023)

COVID-19 Vaccine: A Common Suspect but Rare Culprit in Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
por: Hanna, Mary, et al.
Publicado: (2022)

Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients
por: Squillaci, Domenica, et al.
Publicado: (2023)

Ceftriaxone induced drug rash with eosinophilia and systemic symptoms
por: Guleria, Vivek S., et al.
Publicado: (2014)

Diagnostic criteria for drug rash and eosinophilia with systemic symptoms
por: Pannu, Ashok Kumar, et al.
Publicado: (2017)

Tocilizumab: Toxic erythema and eosinophilia: case report
Publicado: (2020)

Drop of Butyrylcholinesterase Activity after Cyclophosphamide Conditioning as a Predictive Marker of Liver Transplant-Related Complications and Its Correlation with Transplant-Related Mortality in Pediatric Hematopoietic Stem Cell Recipients
por: Maximova, Natalia, et al.
Publicado: (2019)

Drug reaction with eosinophilia and systemic symptoms without skin rash
por: Sasidharanpillai, Sarita, et al.
Publicado: (2015)

Diffuse Exfoliative Rash with Sepsis and Eosinophilia: A Case of Erythroderma?
por: Cho, Jake, et al.
Publicado: (2019)

Pre-Transplant Total Lymphocyte Count Determines Anti-Thymocyte Globulin Exposure, Modifying Graft-versus-Host Disease Incidence and Post-Transplant Thymic Restoration: A Single-Center Retrospective Study
por: Grasso, Antonio Giacomo, et al.
Publicado: (2023)

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!
por: Luherne, Camille, et al.
Publicado: (2019)

P1295: ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY.
por: Maximova, Natalia, et al.
Publicado: (2023)

Editorial: Advances in stem cell therapy: new applications and innovative therapeutic approaches
por: Marcuzzi, Annalisa, et al.
Publicado: (2023)

Pentaglobin(®) Efficacy in Reducing the Incidence of Sepsis and Transplant-Related Mortality in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study
por: Giorgia, Carlone, et al.
Publicado: (2020)

Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients
por: Maximova, Natalia, et al.
Publicado: (2019)

P1272: DEFIBROTIDE IMPACT ON THE ACUTE GRAFT-VERSUS-HOST DISEASE INCIDENCE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.
por: Squillaci, Domenica, et al.
Publicado: (2023)

Vemurafenib- and Cobimetinib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Metastatic Melanoma
por: Al-Saedy, Miriam, et al.
Publicado: (2023)

Drug Rash with Eosinophilia and Systemic Symptoms: Two Emergency Department Cases
por: Tsyrulnik, Alina, et al.
Publicado: (2011)

Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports
por: Pinheiro, Guiomar, et al.
Publicado: (2020)

Drug reaction with eosinophilia and systemic symptoms (DRESS) in children
por: Francesca, Mori, et al.
Publicado: (2019)

Complete Remission of a Refractory Acute Myeloid Leukemia with Myelodysplastic- and Monosomy 7-Related Changes after a Combined Conditioning Regimen of Plerixafor, Cytarabine and Melphalan in a 4-Year-Old Boy: A Case Report and Review of Literature
por: Grasso, Antonio G., et al.
Publicado: (2018)

Intravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenytoin
por: Santhamoorthy, Ponnusamy, et al.
Publicado: (2012)

Drug Rash with Eosinophilia and Systemic Symptoms Syndrome Due to Anti-TB Medication
por: Kaswala, Dharmesh H.
Publicado: (2013)

Skin rash, eosinophilia, and renal impairment in a patient recently started on allopurinol
por: Jmeian, Ashraf, et al.
Publicado: (2016)

Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms
por: Bixby, Alexandra L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_he3jeua273n9rbsvicskh6ne2r